Business programme partners


Bristol Myers Squibb

Bristol Myers Squibb is the company of breakthroughs – the kind that transform patients` lives. Dedicated to our mission of discovering, developing and delivering life-saving innovations that help patients prevail over serious diseases, we`ll never give up our search for more hope, for more people, around the world.

We focus on innovations, as we believe in the power of science to address some of the most challenging diseases of our time. We have a history of scientific excellence, transforming patient outcomes in major diseases such as cancer, cardiovascular disease, HIV and HCV. We pioneered a class of medicines that harnesses the power of the immune system to treat cancer.

Generating new ideas and thinking differently are at the heart of everything we do for patients. We are driven by the knowledge that our efforts can make the difference for a patient.

Alisa Dzhangiryants

Director of Market Access & Pricing Department Bristol Myers Squibb

Alisa Dzhangiryants has been working in the pharmaceutical market for over 18 years. She joined Bristol-Myers Squibb in 2012 as a Project Manager for Immunology & Oncology. In 2014, she moved to the position of the Head of the group of Regional Market Access Managers.

Since 2017, he has been the Director of Market Access and Pricing Department.

Alisa graduated from the First Moscow State Medical University named after I. M. Sechenov with a PhD in Pharmaceutical Sciences.

Boehringer Ingelheim

Boehringer Ingelheim concentrates on developing innovative therapies to improve the health and quality of life of humans and animals. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. The Company has the freedom to pursue its long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where it can do the most good.

Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 52,000 employees create value through innovation daily for the three business areas Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. Investing in R&D the Company develops the breakthrough therapy to improve and extend patients’ lives.

Boehringer Ingelheim realizes more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, the Company accelerates the development of the next medical breakthrough that will transform the lives of patients now, and in generations to come. 

Read more:

Oliver Koehncke

Oliver Koehncke graduated from the Faculty of Political Science at the University of Economics in Budapest. He holds a master degree of international relations and Macroeconomics from the University of Potsdam – specialized in Eastern Europe. He is fluent in English, Hungarian, Russian, Ukrainian and Polish. He is passionate about long-distance swimming and military history.

Oliver Koehncke joined Boehringer Ingelheim in 1997. He began his career in the Central European branch office in Vienna. Since then he had been assigned to several functions in marketing and sales in different countries. In 2007 he became a Senior Regional Business Manager with main focus on Central and Eastern Europe. In 2009 he returned to Poland, where he took over the position of General Director of Boehringer Ingelheim Poland. In the years 2017-2018 he was also the General Director in Boehringer Ingelheim Ukraine. Currently, from January 2020, he holds the position of General Director of Boehringer Ingelheim Russia.

Additional responsibilities:

From September 2020 Oliver Koehncke holds a position of Deputy Chairman of the Committee on Pharmaceuticals and Healthcare of the Russian-German Chamber of Commerce.

In September 2021, Oliver Koehncke was elected a member of the Board of Directors of the Association of International Pharmaceutical Manufacturers (AIPM).

NPO Petrovax Pharm LLC

Petrovax is a Russian full-cycle biopharmaceutical company with 25 years of successful experience. It was founded in 1996 by a group of Russian scientists. Since 2014, the company has been a part of the Interros Group.

The product portfolio includes original pharmaceutical products and vaccines, generics and dietary supplements. The company has its own research center and investment program for R&D, and holds more than 20 new molecule and manufacturing process patents. The company's complex for manufacturing of APIs and finished dosage forms is located in the Moscow region and operates in full compliance with international GMP standards. Petrovax has over 800 employees.

Petrovax's partners are the world's leading pharmaceutical companies: Pfizer, Abbott, Boehringer Ingelheim. Petrovax is the largest Russian exporter of original medicinal products. The company exports products to the countries of the EAEU, the Middle East and the EU.

In 2020-2021 Petrovax conducted large-scale trials of coronavirus vaccine and original medicines products against COVID-19 in Russia and the EU.

Mikhail Tsyferov

President, Member of the Board of Directors, NPO Petrovax Pharm LLC (part of the Interros Group) Managing Director, Winter Capital Fund Private investor in several healthtech, edutech and fintech projects

Before joining Petrovax in 2018, Mikhail Tsyferov gained extensive experience in a number of large investment companies.

From 2018 to present – President of NPO Petrovax Pharm LLC (part of the Interros Group), Member of the Board of Directors.

From 2016 to present – Managing Director of the Winter Capital Fund.

From 2008 to 2016 – manager of the investment department of Interros.

From 2007 to 2008 – employee of the capital markets department at Renaissance Capital.

Acted as an investor in more than 20 Private equity / VC transactions.

He graduated from the School of International Economic Relations of MGIMO (Moscow State Institute of International Relations) in 2007.

Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Katerina Pogodina

Managing Director Russia & CIS, Janssen, pharmaceutical division of Johnson & Johnson, Director General Johnson & Johnson LLC

Novartis Group Russia

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 769 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 142 nationalities work at Novartis around the world. Find out more at or on Facebook, Instagram and YouTube social media NovartisRussia account pages.

Natalia Kolerova

Country President of Novartis Group Russia General Manager of the Novartis Oncology in Russia, Ukraine and CIS countries

Natalia Kolerova was appointed Country President of Novartis Group Russia in September 2019. Natalia is also the General Manager of the Oncology business division of the company and holds the position of General Director of Novartis Pharma LLC in Russia.

Natalia joined Novartis in 2008 as the Head of the Specialties Business unit. Subsequently, Natalia served as the Head of the Market Access function and was responsible for ensuring the availability of drugs in the oncological portfolio of the company at the federal and regional levels.

Prior to joining Novartis, Natalia held senior positions in the Russian offices of the international pharmaceutical companies Abbott Lababorats (Abbott Lab SA) and Sanofi-Aventis (Sanofi-Aventis).

Natalia graduated from the I.M. Sechenov First Moscow State Medical University majoring in Pharmacy, as well as Lomonosov Moscow State University, majoring in Sociology. Natalia also holds a MBA degree.


GSK is a science-led global healthcare company with a special purpose – to help people do more, feel better, live longer. Being headquartered in the UK GSK operates in more than 150 countries and has 3 global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Around 100 000 employees work for GSK around the world with more than 16,000 people working in R&D.

GSK has been operating in Russia since the 1980s and has now around 70 Rx products registered in the country. Our pharmaceutical business in Russia is presented in the following therapeutic areas: HIV, respiratory (asthma, COPD, allergic rhinitis), infectious diseases (antibacterial and antiviral medicines, vaccines), rheumatology and other.

GSK is among industry leaders in terms of investments in clinical trials in Russia.

Sean Reilly

VP & General Manager

Sean Reilly joined GSK Pharma Russia as VP & General Manager on August 1, 2020. Sean reports to Luis Arosemena, SVP Emerging Markets Global Pharma Executive, and leads Russia`s RLT team.

In his role, Sean is responsible for leading Russia's growth agenda across CEP, Respiratory, HIV, Vaccines, and Oncology. He will continue working on "Firebird", Russia accelerated development program, which aims to triple GSK business growth in Russia.

Sean was born in Ireland.

At 22 he moved to Colombia and began working in the pharmaceutical industry as a Medical representative. Later Sean held various positions in sales and marketing. Having worked for GSK for 24 years, Sean has strong experience and expertise in pharmaceutical industry. 14 years ago he was appointed to the position of General Manager GSK Colombia.

Before moving to Moscow, Sean held position of General director GSK Mexico.

“AstraZeneca Pharmaceuticals” LLC

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Irina Panarina

General Manager AstraZeneca Russia and Eurasia

Since May 2017, Irina Panarina has been General Manager of AstraZeneca, Russia and Eurasia. Irina is responsible for AstraZeneca's business in Russia and Eurasia.

Irina has worked for AstraZeneca since 2009. In October 2015, she joined the Russian team as Cardiovascular and Metabolic Disease Business Unit Head. Before coming to Russia, Irina held the position of General Manager at AstraZeneca Ukraine.

Prior to joining AstraZeneca, Irina held regional roles at GSK Pharma headquarters in London, UK.

Irina has work experience in marketing, management and human resources development.

She has degrees from Newcastle University and South Bank University; she also has an MBA from INSEAD Business School.

Since February 2018, Irina has been a member of the General Council of the All-Russia Public Organization “Business Russia” and since December 2019 – a member of the Coordination Council. In March 2018, she was elected as the Business Ambassador of “Business Russia” to Sweden.


Philips ((NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2020 sales of EUR 19,5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at